What does JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG do?

JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG is a healthcare practice in Roeselare. Private Limited, started on 24 March 2010, 1 establishment.

What is the address of JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG?

The registered office of JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG is located at Guido Gezellelaan 96, 8800 Roeselare.

Is JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG still active?

Yes. According to the CBE (31 October 2026) JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG is active, legal situation “Normale toestand”, started on 24 March 2010.

Is JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG registered on Peppol?

Yes, JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG is registered on the Peppol network with ID 0208:0824334011.

What is the enterprise number of JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG?

The enterprise number of JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG is BE0824334011.

Who are the directors of JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG?

According to the 2025 annual accounts, the directors of JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG are: Johan Debrabandere.

Is JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 24 March 2010; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG make in 2025?

JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG posted a profit after taxes of € 510,214 in financial year 2025.

What is the revenue of JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG?

As a small company, JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 689,788.

JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG

Q: When was JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG founded?

JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG was founded on 24 March 2010.

Dossier JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG, printed on 31 October 2026 from databakkes.be/en/0824334011/johan-debrabandere-apotheker-klinisch-bioloog. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG from Roeselare, company number BE0824334011, closed financial year 2025 with a result of € 510,214 after tax. For that financial year JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG recorded a gross margin of € 689,788 and equity of € 3.2 million. Compared with financial year 2024, the result moved from € 439,740 to € 510,214. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on September 28, 2026.

What it is worth Growing

€ 3.2 million

▲ 17% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 510,214

▲ 16% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1.3 million

▲ 68% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 54,000 paid out

11 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 34,824

▲ € 32,573 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 1,049

▼ 8% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 53,283

▲ 7% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2023	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 550,900 Gross margin 2023: € 550,900 First fiscal year in the series	€ 450,556 Gross margin 2023: € 450,556 ▼ 18% vs 2023 (€ 550,900) Unfavourable step	€ 636,012 Gross margin 2024: € 636,012 ▲ 41% vs 2023 (€ 450,556) Favourable step	€ 689,788 Gross margin 2025: € 689,788 ▲ 8% vs 2024 (€ 636,012) Favourable step	▲ 8%
Profit after taxes	€ 343,248 Profit after taxes 2023: € 343,248 First fiscal year in the series	€ 303,043 Profit after taxes 2023: € 303,043 ▼ 12% vs 2023 (€ 343,248) Unfavourable step	€ 439,740 Profit after taxes 2024: € 439,740 ▲ 45% vs 2023 (€ 303,043) Favourable step	€ 510,214 Profit after taxes 2025: € 510,214 ▲ 16% vs 2024 (€ 439,740) Favourable step	▲ 16%
Equity	€ 2,066,863 Equity 2023: € 2,066,863 First fiscal year in the series	€ 2,338,240 Equity 2023: € 2,338,240 ▲ 13% vs 2023 (€ 2,066,863) Favourable step	€ 2,752,980 Equity 2024: € 2,752,980 ▲ 18% vs 2023 (€ 2,338,240) Favourable step	€ 3,209,194 Equity 2025: € 3,209,194 ▲ 17% vs 2024 (€ 2,752,980) Favourable step	▲ 17%
Total debts	€ 91,771 Total debts 2023: € 91,771 First fiscal year in the series	€ 105,650 Total debts 2023: € 105,650 ▲ 15% vs 2023 (€ 91,771) Unfavourable step	€ 76,322 Total debts 2024: € 76,322 ▼ 28% vs 2023 (€ 105,650) Favourable step	€ 108,332 Total debts 2025: € 108,332 ▲ 42% vs 2024 (€ 76,322) Unfavourable step	▲ 42%
Cash	€ 1,025,496 Cash 2023: € 1,025,496 First fiscal year in the series	€ 805,894 Cash 2023: € 805,894 ▼ 21% vs 2023 (€ 1,025,496) Unfavourable step	€ 776,339 Cash 2024: € 776,339 ▼ 4% vs 2023 (€ 805,894) Unfavourable step	€ 1,304,046 Cash 2025: € 1,304,046 ▲ 68% vs 2024 (€ 776,339) Favourable step	▲ 68%
Land & buildings	€ 252,849 Land & buildings 2023: € 252,849 First fiscal year in the series	€ 236,965 Land & buildings 2023: € 236,965 ▼ 6% vs 2023 (€ 252,849) Unchanged	€ 232,148 Land & buildings 2024: € 232,148 ▼ 2% vs 2023 (€ 236,965) Unchanged	€ 212,753 Land & buildings 2025: € 212,753 ▼ 8% vs 2024 (€ 232,148) Unchanged	▼ 8%
Retained profit	€ 2,054,463 Retained profit 2023: € 2,054,463 First fiscal year in the series	€ 2,325,840 Retained profit 2023: € 2,325,840 ▲ 13% vs 2023 (€ 2,054,463) Favourable step	€ 2,740,580 Retained profit 2024: € 2,740,580 ▲ 18% vs 2023 (€ 2,325,840) Favourable step	€ 3,196,794 Retained profit 2025: € 3,196,794 ▲ 17% vs 2024 (€ 2,740,580) Favourable step	▲ 17%
Dividend	€ 51,600 Dividend 2023: € 51,600 First fiscal year in the series	€ 31,666 Dividend 2023: € 31,666 ▼ 39% vs 2023 (€ 51,600) Unchanged	€ 25,000 Dividend 2024: € 25,000 ▼ 21% vs 2023 (€ 31,666) Unchanged	€ 54,000 Dividend 2025: € 54,000 ▲ 116% vs 2024 (€ 25,000) Unchanged	▲ 116%
Bank debt	€ 0 Bank debt 2023: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 252 Bank debt 2024: € 252 Unchanged (€ 0) Unfavourable step	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 252) Favourable step	▼ 100%
Balance sheet total	€ 2,158,634 Balance sheet total 2023: € 2,158,634 First fiscal year in the series	€ 2,443,890 Balance sheet total 2023: € 2,443,890 ▲ 13% vs 2023 (€ 2,158,634) Unchanged	€ 2,829,301 Balance sheet total 2024: € 2,829,301 ▲ 16% vs 2023 (€ 2,443,890) Unchanged	€ 3,317,526 Balance sheet total 2025: € 3,317,526 ▲ 17% vs 2024 (€ 2,829,301) Unchanged	▲ 17%

Key figures of JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG?

What happened at JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Sep 28, 2026 New annual accounts for financial year 2025: profit of € 510,214 (▲ 16% vs 2024). filed late Source: NBB ↗
Apr 1, 2010 New establishment in Roeselare. KBO
2010 Johan Debrabandere became a director. NBB
Mar 24, 2010 Start of the company according to the CBE. KBO

In short

From € 343,248 profit in 2023 to € 510,214 profit in 2025.

Paid € 717,847 in corporate taxes since 2023.

Best year ever: 2025, with € 510,214 profit.

Paid out € 162,266 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Johan Debrabandere

JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG

Behind JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG is Johan Debrabandere.

Directors

According to the 2025 annual accounts

Johan Debrabandere

Bestuurder

since 2010

Establishments

Establishment units

Physical locations of this company

Registered office

Guido Gezellelaan 96

8800 Roeselare

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0824.334.011

VAT number

BE 0824.334.011

Registered office

Guido Gezellelaan 96, 8800 Roeselare

Names & denominations

JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

24 March 2010

Peppol

Active · Active since 19 Sept 2026

Activities · NACE

Activiteiten van medische beeldvorming en medische laboratoria

Activiteiten van medische laboratoria

Detailhandel in farmaceutische producten

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

View on CBE Public ↗ Annual accounts (NBB) ↗

JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG

Financials

What happened to JOHAN DEBRABANDERE - APOTHEKER KLINISCH BIOLOOG?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions